Targeting epidermal growth factor receptor in the management of lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pulmonology

Background:

• Epidermal growth factor receptor (EGFR) mutations are key drivers in pulmonary adenocarcinoma development and progression.
• EGFR tyrosine kinase inhibitors (TKIs) offer significant benefits in tumor response, progression-free survival (PFS), and quality of life for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
• EGFR TKIs have replaced platinum-based chemotherapy as the standard first-line treatment for EGFR mutation-positive NSCLC based on robust clinical trial data.

Purpose of the Study:

• To review the efficacy of EGFR TKIs in treating EGFR mutation-positive NSCLC.
• To discuss the challenge of acquired resistance to EGFR TKIs.
• To outline post-progression treatment strategies for NSCLC patients who develop resistance.

Main Methods:

• Systematic review of randomized clinical trials comparing EGFR TKIs to chemotherapy.
• Analysis of data on treatment response, PFS, and quality of life.
• Literature search for studies investigating resistance mechanisms and subsequent treatment options.

Main Results:

• EGFR TKIs demonstrate superior outcomes compared to platinum-based chemotherapy in EGFR-mutated NSCLC.
• Acquired resistance to EGFR TKIs is nearly universal in patients with NSCLC.
• Post-progression therapies may involve combinations of local treatments, chemotherapy, and next-generation EGFR TKIs.

Conclusions:

• EGFR TKIs are a cornerstone of first-line therapy for EGFR-mutated NSCLC.
• Addressing acquired resistance is crucial for improving long-term patient outcomes.
• Multimodal treatment approaches are necessary for managing advanced NSCLC post-TKI progression.